Higher Busulfan Dose Intensity Does Not Improve Outcomes of Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT) Following Fludarabine/Busulfan/Atg (FBA)-Based Reduced Toxicity Conditioning (RTC)

Autor: Hamadani, M., Craig, M., Abraham, J., Tse, W., Cumpston, A., Gibson, L.F., Remick, S.C., Leadmon, S., Elder, P., Hofmeister, C., Penza, S., Andritsos, L., Blum, W., Benson, D.M., Jr., Devine, S.M.
Zdroj: In Biology of Blood and Marrow Transplantation 2011 17(2) Supplement:S306-S306
Databáze: ScienceDirect
Externí odkaz: